(firstQuint)Efficacy and Safety of Flutiform pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma.

 This is a study involving a 12 week treatment phase.

 During the treatment phase subjects receive FLUTIFORM(R) or Sertetide(R).

 Efficacy will be assessed by lung function tests and asthma symptoms, sleep disturbance.

 Safety will be assessed by adverse events, vital signs, lab tests and ECGs.

.

 Efficacy and Safety of Flutiform pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma@highlight

Open, parallel group design.

 The study has a screening phase and a 12 week treatment phase.

 Subjects will be randomised to treatment in a 1:1 ration.

